Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn’s Disease

INTRODUCTION: In the phase 2 CELEST study, positive efficacy results were obtained with the Janus kinase 1 inhibitor upadacitinib for adult patients with moderate to severe Crohn’s disease. We present the health-related quality of life and work productivity improvement results with upadacitinib from...

Descripción completa

Detalles Bibliográficos
Autores principales: Peyrin-Biroulet, Laurent, Louis, Edouard, Loftus, Edward V., Lacerda, Ana, Zhou, Qian, Sanchez Gonzalez, Yuri, Ghosh, Subrata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107073/
https://www.ncbi.nlm.nih.gov/pubmed/33755884
http://dx.doi.org/10.1007/s12325-021-01660-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107073/
https://www.ncbi.nlm.nih.gov/pubmed/33755884
http://dx.doi.org/10.1007/s12325-021-01660-7

Ejemplares similares